NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant
Adaptive Trial Skips Monotherapy Arm, Uses Factorial Design
Executive Summary
Eli Lilly’s drug is one of many anti-inflammatory medicines in late-stage trials against coronavirus but will be the first to be combined with Gilead’s recently approved remdesivir.
You may also be interested in...
Coronavirus Update: Lilly To Seek EUA For Olumiant
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation
Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.
Coronavirus Update: FDA Pulls Hydroxychloroquine Emergency Authorization, Germany Acquires Stake In CureVac
Plus news on the German government's decision to by a 23% stake in mRNA vaccines company CureVac, and Lilly taking Olumiant into Phase III.